Clinical Trial Update: Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant chemotherapy with a PD-1 monoclonal antibody for operable esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• PD-1 monoclonal antibody

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN